Clinical trials: Episodic Migraine Headache
Migraine Headache, Arterial Stiffness
Vitamin K2 Supplementation in Adult Episodic Migraine
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women.
- Conditions
- Migraine Headache, Arterial Stiffness, Vitamin K Deficiency
- Trial name
- ViKEM (NCT05943457)
- Testing
- Vitamin K2 or menaquinone-7
- Where
- Lebanon
- Volunteers
- 160 people
- Sponsor
- Sola Aoun Bahous, M.D. Ph.D.
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Migraine
Comparison of Occipital Nerve and Sphenopalatine Ganglion Blockade
Migraine is a chronic disorder that causes disability. Episodic migraine can be managed by prophylactic medical treatment or interventional pain procedures.
- Trial name
- NCT06243874
- Testing
- greater occipital nerve block, transnasal sphenopalatine ganglion block
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ankara University
Episodic Migraine
DFN-11 Injection in Episodic Migraine With or Without Aura
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
- Trial name
- RESTOR (NCT02569853)
- Testing
- DFN-11
- Where
- 16 sites in United States
- Volunteers
- 268 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Greater Occipital Nerve Block, Sphenopalatine Ganglion Block
Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.
- Conditions
- Greater Occipital Nerve Block, Sphenopalatine Ganglion Block, Episodic Migraine
- Trial name
- NCT06997562
- Testing
- Greater occipital nerve blockade, Sphenopalatine ganglion blockade
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- New Valley University
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine, Migraine Disorder
Tai Chi and Acupuncture on Migraine Attack Prevention and Brain White Matter Changes
The goal of this clinical trial is to determine the effectiveness of Tai Chi training and acupuncture on the migraine attacks and structural brain changes in women with episodic migraine.
- Trial name
- NCT06967909
- Testing
- Tai Chi training, Acupuncture
- Where
- Hong Kong
- Volunteers
- 132 people
- Sponsor
- The Hong Kong Polytechnic University
Migraine
Safety, Efficacy and Pharmacokinetics of ALD403
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
- Trial name
- NCT01772524
- Testing
- ALD403
- Where
- 26 sites in United States
- Volunteers
- 163 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-2 (NCT02614196)
- Testing
- Galcanezumab
- Where
- 113 sites in United States, Argentina and 10 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Migraine Headache
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Migraine is one of the three most disabling diseases worldwide. Constituted by recurrent episodes of headache, characterized by unilateral location, throbbing character, moderate or severe intensity, worsening with physical…
- Trial name
- NCT04698525
- Testing
- Valproate Sodium, Memantine
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Migraine Without Aura, Migraine With Aura
TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）
In this study,189 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of…
- Trial name
- NCT05484349
- Testing
- Tizanidine Hydrochloride
- Where
- 6 sites in China
- Volunteers
- 189 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Episodic Migraine
Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine
The goal of this study is to learn whether Gou-Teng-San (GTS), a traditional herbal medicine, is effective and safe for adults with episodic migraine.
- Trial name
- GTSEM (NCT07496034)
- Testing
- Gou-Teng-San
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Tsai, Chueh-Yi, MD
Migraine Disorders, Migraine Variant
Vestibular System in Migrainous Vertigo Patients
Do migrainous vertigo patients have more pathology in their vestibular system than migraine patients without vertigo? The aim of this study is to compare the vestibular system of migraine patients with and without vertigo in the…
- Conditions
- Migraine Disorders, Migraine Variant, Episodic Recurrent Vertigo
- Trial name
- NCT00901953
- Where
- Norway
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Bergen
Episodic Migraine
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be…
- Trial name
- EStatinMig (NCT06248671)
- Testing
- Atorvastatin 40mg, Atorvastatin 20mg
- Where
- 6 sites in Norway
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- St. Olavs Hospital
Episodic Migraine
Chiropractic Care for Episodic Migraine
Migraine, a chronic intermittent headache disorder, ranks in the top five causes of years lived with disability. One promising non-pharmacologic and integrative treatment for migraine may be chiropractic care due to the…
- Trial name
- NCT06229834
- Testing
- Chiropractic Care, Headache Health Education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Migraine
Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH
This study will compare nortriptyline and amitriptyline for preventing migraine attacks in adults receiving care at Sultan Qaboos University Hospital in Oman.
- Trial name
- NCT07856056
- Testing
- Nortriptyline, Amitriptyline
- Where
- Oman
- Volunteers
- 90 people
- Sponsor
- Sultan Qaboos University
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
- Trial name
- NCT00797667
- Testing
- Telcagepant 140 mg, Telcagepant 280 mg
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Headache
Ketone for Migraine Prevention
Efficacy of a nutritional ketogenic supplement (NKS) in reducing the number, intensity, and duration of migraine headaches in episodic migraine patients.
- Trial name
- NCT05085483
- Testing
- Nutritional Ketogenic Supplement
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Société des Produits Nestlé (SPN)